AQR Capital Management LLC Purchases 769,586 Shares of FibroGen, Inc. (NASDAQ:FGEN)

AQR Capital Management LLC lifted its position in FibroGen, Inc. (NASDAQ:FGEN) by 139.6% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,320,866 shares of the biopharmaceutical company’s stock after buying an additional 769,586 shares during the period. AQR Capital Management LLC owned approximately 1.33% of FibroGen worth $1,179,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently added to or reduced their stakes in the company. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of FibroGen during the second quarter worth about $130,000. Squarepoint Ops LLC bought a new stake in FibroGen in the second quarter worth $145,000. Cubist Systematic Strategies LLC boosted its stake in shares of FibroGen by 3,906.9% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 287,332 shares of the biopharmaceutical company’s stock worth $256,000 after purchasing an additional 280,161 shares during the period. Point72 DIFC Ltd boosted its position in shares of FibroGen by 734.2% during the second quarter. Point72 DIFC Ltd now owns 52,254 shares of the biopharmaceutical company’s stock valued at $47,000 after buying an additional 45,990 shares during the period. Finally, Sei Investments Co. increased its stake in FibroGen by 38.4% in the second quarter. Sei Investments Co. now owns 149,342 shares of the biopharmaceutical company’s stock worth $133,000 after purchasing an additional 41,442 shares during the period. 72.71% of the stock is currently owned by institutional investors.

FibroGen Trading Up 6.0 %

Shares of NASDAQ:FGEN opened at $0.36 on Friday. The company has a market capitalization of $35.87 million, a PE ratio of -0.21 and a beta of 0.70. The business’s fifty day simple moving average is $0.39 and its 200-day simple moving average is $0.94. FibroGen, Inc. has a 12-month low of $0.30 and a 12-month high of $2.93.

FibroGen (NASDAQ:FGEN) last issued its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.09. The business had revenue of $50.64 million for the quarter, compared to analysts’ expectations of $33.00 million. During the same quarter in the previous year, the firm posted ($0.65) EPS. Research analysts predict that FibroGen, Inc. will post -0.91 EPS for the current year.

Analyst Ratings Changes

Separately, StockNews.com assumed coverage on FibroGen in a report on Saturday, October 5th. They issued a “hold” rating for the company.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.